First quarter of 2026
FINANCIAL RESULTS

6 MAY 2026

DISCLAIMER

This Presentation has been prepared by Laboratorios Farmacéuticos ROVI, S.A. (the "Company") and comprises the slides for a presentation concerning the Company and its subsidiaries (the "Group"). For the purposes of this disclaimer, "Presentation" means this document, its contents or any part of it, any oral presentation, any question or answer session and any written or oral material discussed or distributed during the Presentation meeting or otherwise in connection with it.

This Presentation does not constitute or form part of, and should not be construed as, any offer to sell or issue or invitation to purchase or subscribe for, or any solicitation of any offer to purchase or subscribe for any securities of the Company, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision.

The information contained in this Presentation does not purport to be comprehensive. None of the Company, its respective subsidiaries or affiliates, or its or their respective directors, officers, employees, advisers or agents accepts any responsibility or liability whatsoever for, or makes any representation or warranty, express or implied, as to the truth, fullness, accuracy or completeness of the information in this Presentation (or whether any information has been omitted from the Presentation) or any other information relating to the Group, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this Presentation or its contents or otherwise arising in connection therewith. Each of such persons accordingly disclaims all and any liability whatsoever, whether arising in tort, contract or otherwise in respect of this Presentation or any such information.

The information in this Presentation may include forward-looking statements, which are based on current expectations, projections and assumptions about future events. These forward-looking statements as well as those included in any other information discussed in the Presentation are subject to known or unknown risks, uncertainties and assumptions about the Group and its investments, including, among other things, the development of its business, its growth plan, trends in its operating industry, its future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur and actual results, performance or achievements may materially differ from any future results, performance or achievements that may be expressed or implied in this Presentation. No representation or warranty is made that any forward-looking statement will come to pass. Forward-looking statements speak as of the date of this Presentation and no one undertakes to publicly update or revise any such forward-looking statement, whether as a result of new information, future events or otherwise. Accordingly, undue reliance should not be placed on any forward-looking statement contained in this Presentation.

To the extent available, the industry, market and competitive position data contained in this Presentation come from official or third party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company reasonably believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry, market and competitive position data contained in this Presentation come from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the markets in which the Group operates. While the Company reasonably believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change. Accordingly, undue reliance should not be placed on any of the industry, market or competitive position data contained in this Presentation. This Presentation also includes certain alternative performance measures ("APMs") that have not been prepared under IFRS-EU and have not been reviewed or audited by the Company's auditors nor by any independent expert. Moreover, the way the Group defines and calculates these measures may differ to the way similar measures are calculated by other companies. Accordingly, they may not be comparable.

Certain financial and statistical information contained in this Presentation is subject to rounding adjustments. Accordingly, any discrepancies between the totals and the sums of the amounts listed are due to rounding. Certain financial information and operating data relating to the Company contained in this Presentation has not been audited and in some cases is based on management information and estimates, and is subject to change.

No reliance may or should be placed by any person for any purposes whatsoever on this Presentation, or on its completeness, accuracy or fairness. The information in this Presentation is in summary draft form for discussion purposes only. The information and opinions contained in this Presentation are provided as at the date of the Presentation and are subject to verification, correction, completion and change without notice. In giving this Presentation, none of the Company, its subsidiaries or affiliates, or its or their respective directors, officers, employees, advisers or agents, undertakes any obligation to amend, correct or update this Presentation or to provide the recipient with access to any additional information that may arise in connection with it.

Q1 2026 financial results - highlights

€152.5 Mn
Operating revenue
-1.5% vs Q1 2025

- Total revenue stable at €154.7 Mn vs Q1 2025
- CDMO performed strongly: +5% YoY to €37.4 Mn in Q1 2026
- Specialty pharmaceutical business:
  - Okedi® continued its strong momentum: +37% YoY
  - Heparin franchise: -12% YoY due to lower international bemiparin sales
  - Neparvis delivered solid growth: +4% YoY

62.3%
Gross margin
+3.8 pp vs Q1 2025

- Gross profit: +5% YoY reaching €95.0 Mn.
- Gross margin expansion supported by:
  - Revenue from CDTI R&D aid (LAISOLID project)
  - Higher Okedi® contribution
  - Lower LMWH raw material prices
  - Increase in CDMO sales

Key milestones

On April 2026, ROVI announced the closing of the Asset Purchase Agreement for the acquisition of a pharmaceutical manufacturing facility located in Phoenix, Arizona (USA)

2026 guidance update

ROVI expects its operating revenue to increase by a low- to mid-single-digit percentage vs 2025

To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 33-37) of the press release on the financial results for the first quarter of 2026. Said document is available on ROVI's website and may be accessed on the following link: https://www.rovi.es/en/shareholders-investors/financial-business-information.

First quarter of 2026
Business Performance

Juan López-Belmonte
Chairman and Chief Executive Officer

Performance of the specialty pharmaceutical business



ROVI aspires to become a benchmark player in the LMWH field worldwide

Prescription-based sales
-6% vs Q1 2025

Heparine franchise[1]
-12% vs Q1 2025

Low molecular weight heparin (LMWH) sales
-13% vs Q1 2025



Heparin sales represented 40% of operating revenue in Q1 2026

Bemiparin	Enoxaparin biosimilar
• **Over 70 years of expertise** in heparin-based drug development • Only 2nd generation LMWH; **clinical differentiated from other competitors** • Commercial **presence in +60 countries**	• Approved in **26 countries in Europe** and **33 in the rest of the world** • Directly marketed in **Germany, UK, Italy, France, Austria, Portugal and Spain** • Expansion in other markets through **out licensing agreements with international partners: 82 territories signed**

Outlook 2026: LMWH sales expected to decline by a high single-digit percentage vs. 2025, due to lower orders from partners and pricing pressure

(1) Heparin franchise includes low molecular weigth heparins and other heparins. Other heparins are reported in the "Contrast agents and other hospital products" line.

Okedi®: Key growth driver in Q1 2026



Strong commercial momentum	• Continued growth across key European markets
Differentiated clinical value	• Rapid onset with immediate and sustained plasma levels from Day 1 without the need for oral supplementation or loading dose • High efficacy balanced with good tolerability and functioning improvement in the short and long-term treatment of schizophrenia • Low relapse, rehospitalization, and discontinuation due to treatment emergent adverse events (TEAEs) rates
Peak sales	• €100–200 Mn

Value added CDMO services

Our global manufacturing network

ROIS

ROIS Julián Camarillo (Madrid)
Fill & finish of PFS[1] and cartridges

ROIS San Sebastián de los Reyes
Fill & finish of PFS, cartridges and vials

ROIS Alcalá de Henares
Center of excellent for injectable packaging and assembly

ROIS Granada
API Biologics manufacturing site

ROIS Phoenix
High-potent vial manufacture, fill&Lyo and packaging

Closing date: April 1, 2026

CDMO revenue performance



(1) PFS stands for "Prefilled syringe"-

ISM® Platform opens up new avenues of growth for ROVI

Overview

- Internally-developed and patented innovative drug-release technology, ISM®[1], which allows for the sustained release of compounds administered by injection
- Based on two separate syringes containing, respectively, (i) the drug and polymer (solid state) and (ii) the solvent (liquid state)
- Potential wide applicability of ISM® technology to new chronic therapeutic areas, including psychiatry and oncology
- 505(b)(2) path of approval for candidates leveraging ISM® technology

Product	Potential Indication	Current Situation	Key Milestones
Risperidone ISM®, monthly	**Schizophrenia**	Aproved	Marketed in Europe, and in Australia & Taiwan
Letrozole ISM®, annual	**Breast Cancer**	Clinical development on hold	Phase I: Superior oestrogen suppression vs Femara®
Letrozole SIE[2], quarterly	**Breast Cancer**	Completion of Phase I	Phase I: positive readout confirms superior estrogen suppression vs Femara® and allows progression to phase III clinical trial
Risperidone ISM®, quarterly	**Schizophrenia**	Completion of Phase I	Phase I: positive readout allows progression to Phase III clinical trial
Concentrated on improving posology for already approved compounds, which benefits risk / reward profile			
Multiple FDA / GMP approved facilities to support the platform			

Key Company Highlights of ISM® Platform

1	**Predictability**	Pop PK[3] model & simulations already validated for Risperidone-ISM® in Phase I & II Clinical Program	Expected high success rate in Phase III in new developments
2	**Usability**	Improved stability	No cold chain needed
3	**Flexibility**	Selecting the most convenient posology depending on clinical needs	From 1 to 12 months administration
4	**Improved Clinical Management**	Long-acting injection (1-12 months) plasma therapeutic levels from day 1	Rapid onset & sustained clinical effect
5	**Vertical Integration**	Technological barriers (e.g. power filling) Strong IP Manufacturing capabilities	Protected technology Fully integrated manufacturing plants

(1) ISM® stands for *In Situ Microimplants.*
(2)Superior Inhibition of Estrogen
(3) PK stands for pharmacokinetic

First quarter of 2026
Financial Performance

Javier López-Belmonte
Deputy Chairman and Chief Financial Officer

Revenue level affected by the performance of the prescription-based pharmaceutical products



(*) Note:. "Other operating revenue" includes service activities that are not material to the Group.
To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 33-37) of the press release on the financial results for the first quarter of 2026. Said document is available on ROVI's website and may be accessed on the following link: https://www.rovi.es/en/shareholders-investors/financial-business-information.

Gross margin uplift from R&D aid, Okedi®, lower LMWH raw material prices and the increase in CDMO activity

Gross profit and Gross margin



Gross profit increased 5% to €95.0 Mn in Q1 2026.

Gross margin rose by 3.8 pp to 62.3% in Q1 2026, partly driven by CDTI R&D aid. Excluding “Other income”, gross margin increased 2.5 pp to 60.8%, mainly due to (i) higher Okedi® contribution, (ii) lower LMWH raw material costs, and (iii) increased CDMO activity.

SG&A with continued R&D commitment

SG&A expenses



R&D expenses



SG&A increased 18% to €63.6 Mn in Q1 2026, driven by:

- "Employee benefit expenses (excl. R&D)": +9% YoY, due to (i) wage increases, and (ii) the hiring of new CDMO personnel; and
- "Other operating expenses (excl. R&D)": +30% YoY impacted by (i) lower operating expenses in Q1 2025 vs Q1 2026 following the temporary closure of the Madrid facility, and (ii) non-recurring expenses mainly associated with the write-off of assets that are no longer operational. Excluding non-recurring expenses, "Other operating expenses (excl. R&D)" increased by 21.0% in the period.

2026 SG&A Outlook: excluding ROIS Phoenix from the Group, it is expected to increase by a mid- to high-single-digit percentage vs 2025.

R&D expenses increased by 79% to €11.2 Mn in Q1 2026. These expenses are related to the preparation for the development of the phase III clinical trial of Letrozole SIE.

(1) Source: https://www.feique.org/wp-content/uploads/2024/11/XXI-CONVENIO-GENERAL-DE-LA-INDUSTRIA-QUIMICA.pdf

To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 33-37) of the press release on the financial results for the first quarter of 2026. Said document is available on ROVI's website and may be accessed on the following link: https://www.rovi.es/en/shareholders-investors/financial-business-information.

EBITDA, EBIT & Net Profit analysis

EBITDA



EBIT





Net Profit



Pre-R&D analysis(1)



(1) EBITDA, EBIT and Net profit "pre-R&D" calculated excluding R&D expenses in Q1 2026 and Q1 2025.
To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on pages 14-15 and Appendix 2 (pages 33-37) of the press release on the financial results for the first quarter of 2026. Said document is available on ROVI's website and may be accessed on the following link: https://www.rovi.es/en/shareholders-investors/financial-business-information.

Capital expenditure and Cash Flow

CAPEX Evolution
-7% vs Q1 2025

Main investments

- New filling lines and operations expansion
- Glicopepton
- ISM® Industrialisation



Glicopepton
New filling lines and operations expansion
ISM® Industrialisation
Maintenance capex

Cash flow evolution



To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 18-20 and Appendix 2 (pages 33-37) of the press release on the financial results for the first quarter of 2026. Said document is available on ROVI's website and may be accessed on the following link: https://www.rovi.es/en/shareholders-investors/financial-business-information.

Debt overview

Debt breakdown by source (%)



Total debt
€114.4 Mn

Debt maturities



Net debt of **€14.9 Mn** as of 31 March 2026 vs €21.9 Mn as of 31 December 2025

ROVI will put a proposal to the General Shareholders' Meeting for distribution of a dividend of €0.9594 per share entitled to receive it, charged to the 2025 profit and distributable reserves

To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on pages 17-18 and Appendix 2 (pages 33-37) of the press release on the financial results for the first quarter of 2026. Said document is available on ROVI's website and may be accessed on the following link: https://www.rovi.es/en/shareholders-investors/financial-business-information.

Outlook and closing remarks

2026 Outlook update

ROVI expects its operating revenue to increase by a low- to mid-single-digit percentage vs 2025

Closing remarks

- Strong momentum in CDMO business: consistent and focused execution
- Value creation from the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA)
- Vertical integration of the heparin division to enhance cost efficiency and improve competitiveness
- Sustained growth of the specialty pharmaceutical business, driven by Okedi®
- Strong R&D investment, with two phase III clinical trials ongoing

Alternative performance measures

In addition to the financial information prepared in accordance with International Financial Reporting Standards ("IFRSs") taken from our financial statements, this document includes certain alternative performance measures ("APMs") as defined in the ESMA (European Securities and Markets Authority) Guidelines on Alternative Performance Measures of 5 October, 2015 (ESMA/2015/1415), as well as some non-IFRS financial indicators. The financial measures contained in this document that are considered APMs or non-IFRS financial indicators have been prepared on the basis of the ROVI Group's financial information but are not defined or set out in detail within the framework of the applicable financial information and have not been audited or reviewed by ROVI's auditors.

These APMs are considered figures that have been adjusted in respect of those that are presented in accordance with the International Financial Reporting Standards endorsed by the European Union (IFRS-EU), which form the applicable accounting framework for the consolidated financial statements of the ROVI Group. Therefore, the reader should consider them to complement the latter but not to replace them.

ROVI uses these APMs and non-IFRS financial indicators to plan, oversee and assess its performance. ROVI considers the APMs and non-IFRS financial indicators to be useful to allow the management team and investors to compare the past or future financial performance, the financial situation and the cash flows. Notwithstanding, these APMs and non-IFRS financial indicators are considered complementary and are not intended to replace IFRS measures. Furthermore, other companies, including some in ROVI's sector, may calculate such measures differently, which reduces their usefulness for comparative purposes.

To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used by ROVI, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on Appendix 2 (pages 33-37) of the press release on the financial results for the first quarter of 2026. Said document is available on ROVI's website and may be accessed on the following link: (https://www.rovi.es/en/shareholders-investors/financial-business-information).

For further information, please contact:

Juan López-Belmonte
Chairman and Chief Executive Officer
www.rovi.es

Javier López-Belmonte
Deputy Chairman and Chief Financial Officer
www.rovi.es

Marta Campos
Head of Finance
mcampos@rovi.es
www.rovi.es

Beatriz de Zavala
Investor Relations Analyst
bdezavala@rovi.es
www.rovi.es

Victoria López-Belmonte
Investor Relations Analyst
vlopez-belmonte@rovi.es
www.rovi.es